Changes in acetylcholinesterase in experimental autoimmune myasthenia gravis and in response to treatment with a specific antisense

被引:3
|
作者
Blotnick, Edna [1 ]
Hamra-Amitai, Yasmine [2 ,3 ]
Wald, Chen [2 ,3 ]
Brenner, Talma [2 ,3 ]
Anglister, Lili [1 ]
机构
[1] Hebrew Univ Jerusalem, Sch Med, Inst Med Res, Dept Med Neurobiol,IMRIC, IL-91010 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Dept Neurol, IL-91010 Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Agnes Ginges Ctr Human Neurogenet, Hadassah Med Ctr, IL-91010 Jerusalem, Israel
关键词
acetylcholine receptor; acetylcholinesterase molecular forms; EAMG; myasthenia gravis; neuromuscular junction; FROG NEUROMUSCULAR-JUNCTIONS; SKELETAL-MUSCLE; MOLECULAR-FORMS; UP-REGULATION; END-PLATE; RAT; RECEPTOR; EXPRESSION; NERVE; SLOW;
D O I
10.1111/j.1460-9568.2012.08218.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Controlled regulation of synaptic nicotinic acetylcholine receptors (AChRs) and acetylcholinesterase (AChE), together with maintenance of a dynamic balance between them, is a requirement for proper function of cholinergic synapses. In the present study we assessed whether pathological changes in AChR perturb this balance, and whether such changes can be corrected. We studied the influence of AChR loss, caused by experimental autoimmune myasthenia gravis (EAMG), on muscle AChE, as well as the reciprocal effect of an antisense targeted towards AChE on both AChR and AChE at the neuromuscular synapse. The extensor digitorum longus (EDL) muscles of EAMG Lewis rats were isolated, and AChE levels and isoform compositions were examined. Although AChE levels in the muscles of healthy and EAMG rats were similar, marked changes were observed in isoform composition. Healthy EDL muscles contained globular (G1,2, G4) and asymmetric (primarily A12) isoforms. G1,2-AChE was significantly reduced in EAMG muscles, whereas both G4- and A12-AChE remained unchanged. Treatment of EAMG rats with the antisense EN101 resulted in decreased total muscle AChE, with recovery in G1,2 and reduction in A12-AChE. AChE/AChR ratios were determined at the neuromuscular junctions (NMJ). The decrease in AChR levels that occurred as the disease progressed resulted in a dramatic increase in this ratio, and a significant recovery towards normal ratios occurred after EN101 treatment. This improvement was primarily due to increased synaptic AChR content. Our findings emphasise the tight connection between AChR and AChE at the myasthenic NMJ, and the importance of the AChE/AChR ratio in maintaining the required cholinergic balance.
引用
收藏
页码:3077 / 3085
页数:9
相关论文
共 50 条
  • [21] Basic treatment of myasthenia gravis - Acetylcholinesterase inhibitors
    Janzen, RWC
    AKTUELLE NEUROLOGIE, 1998, 25 : S42 - S45
  • [22] The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis
    Katz, Natalie K.
    Barohn, Richard J.
    NEUROPHARMACOLOGY, 2021, 182
  • [23] ROCK inhibitor abolishes the antibody response in experimental autoimmune myasthenia gravis
    Li, Heng
    Zhang, Min
    Wang, Cong-Cong
    Li, Xiao-Li
    Zhang, Peng
    Yue, Long-Tao
    Miao, Shuai
    Dou, Ying-Chun
    Li, Yan-Bin
    Duan, Rui-Sheng
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2016, 74 : 106 - 113
  • [24] Further developments with antisense treatment for myasthenia gravis
    Sussman, Jon
    Argov, Zohar
    Wirguin, Yitzhak
    Apolski, Slobodan
    Milic-Rasic, Vedrana
    Soreq, Hermona
    MYASTHENIA GRAVIS AND RELATED DISORDERS II, 2012, 1275 : 13 - 16
  • [25] Antisense treatment for myasthenia gravis - Experience with Monarsen
    Sussman, Jon D.
    Argov, Zohar
    Mckee, David
    Hazum, Eli
    Brawer, Solli
    Soreq, Hermona
    MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE, 2008, 1132 : 283 - 290
  • [26] Ephedrine treatment for autoimmune myasthenia gravis
    Lipka, Alexander F.
    Vrinten, Charlotte
    van Zwet, Erik W.
    Schimmel, Kirsten J. M.
    Cornel, Martina C.
    Kuijpers, Marja R.
    Hekster, Yechiel A.
    Weinreich, Stephanie S.
    Verschuuren, Jan J. G. M.
    NEUROMUSCULAR DISORDERS, 2017, 27 (03) : 259 - 265
  • [27] The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis
    Xiao, Bao-Guo
    Duan, Rui-Sheng
    Zhu, Wen-Hua
    Lu, Chuan-Zhen
    CELLULAR IMMUNOLOGY, 2006, 241 (02) : 95 - 101
  • [28] CONTENT AND RELEASE OF ACETYLCHOLINESTERASE IN SKELETAL-MUSCLE OF RATS WITH EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    CARTER, J
    LENNON, VA
    SCHREIBER, P
    BRIMIJOIN, S
    EXPERIMENTAL NEUROLOGY, 1982, 75 (02) : 490 - 500
  • [29] ANTIIDIOTYPIC ANTIBODIES IN THE STUDY AND TREATMENT OF EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    SOUROUJON, MC
    FUCHS, S
    METHODS IN ENZYMOLOGY, 1989, 178 : 433 - 448
  • [30] IMMUNOLOGICAL MECHANISM OF IMMUNOSUPPRESSIVE TREATMENT OF EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    TARRABHAZDAI, R
    SCHWARTZ, M
    FUCHS, S
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1977, 13 (10): : 1043 - 1043